Review on Current Status of Echinocandins Use

Mroczyńska, Martyna; Brillowska-Dąbrowska, Anna

doi:10.3390/antibiotics9050227

Cited by 47 publications

(50 citation statements)

References 116 publications

(192 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most naturally expressed lipopeptides have a cyclic hexapeptide head attached to a single lipid chain, responsible for their antifungal activity [27]. Thus, the cyclization of the peptide unit that occurs in many lipopeptides that are expressed by bacteria increases in vivo stability compared to their linear counterparts.…”

Section: Echinocandins As Tools For Treating Candida Auris Infectionsmentioning

confidence: 99%

“…These molecules are particularly indicated for the treatment of invasive infections caused by Candida, especially in hemodynamically unstable patients after triazoles treatment. [27].…”

Section: Echinocandins As Tools For Treating Candida Auris Infectionsmentioning

confidence: 99%

“…Echinocandins, in general, manage to destabilize the integrity of the cell wall and reduce its stiffness, consequently causing cell lysis due to low osmotic pressure. [27]. Notoriously, caspofungins are considered effective against yeasts that form biofilms.…”

Section: Echinocandins As Tools For Treating Candida Auris Infectionsmentioning

confidence: 99%

“…However, they are inactive against C. auris biofilms, an unexpected event, since these molecules are normally effective against Candida species biofilms [43,44]. In addition, they are not used as a treatment for urinary infections caused by C. auris, as they fail to reach the required therapeutic concentrations of these compounds in the urine [27]. The survival C. auris capability in hospital environments may be related to yeast biofilm formation.…”

Section: Echinocandins As Tools For Treating Candida Auris Infectionsmentioning

confidence: 99%

“…Similar to caspofungin, micafungin originated from the cleavage and addition of an N-acylated side chain to the natural hexapeptide derived from C. empetri. [27]. The FDA approved this molecule in March 2005 for use in adults and in 2013 for pediatric treatment.…”

Section: Echinocandins As Tools For Treating Candida Auris Infectionsmentioning

confidence: 99%

See 4 more Smart Citations

Echinocandins as Biotechnological Tools for Treating Candida auris Infections

Cândido

Affonseca

Cardoso

et al. 2020

JoF

View full text Add to dashboard Cite

Candida auris has been reported in the past few years as an invasive fungal pathogen of high interest. Its recent emergence in healthcare-associated infections triggered the efforts of researchers worldwide, seeking additional alternatives to the use of traditional antifungals such as azoles. Lipopeptides, specially the echinocandins, have been reported as an effective approach to control pathogenic fungi. However, despite its efficiency against C. auris, some isolates presented echinocandin resistance. Thus, therapies focused on echinocandins’ synergism with other antifungal drugs were widely explored, representing a novel possibility for the treatment of C. auris infections.

show abstract

Section: Echinocandins As Tools For Treating Candida Auris Infectionsmentioning

confidence: 99%

“…These molecules are particularly indicated for the treatment of invasive infections caused by Candida, especially in hemodynamically unstable patients after triazoles treatment. [27].…”

Section: Echinocandins As Tools For Treating Candida Auris Infectionsmentioning

confidence: 99%

Section: Echinocandins As Tools For Treating Candida Auris Infectionsmentioning

confidence: 99%

Section: Echinocandins As Tools For Treating Candida Auris Infectionsmentioning

confidence: 99%

Section: Echinocandins As Tools For Treating Candida Auris Infectionsmentioning

confidence: 99%

See 3 more Smart Citations

Echinocandins as Biotechnological Tools for Treating Candida auris Infections

Cândido

Affonseca

Cardoso

et al. 2020

JoF

View full text Add to dashboard Cite

show abstract

Natural Products That Contain Higher Homologated Amino Acids

Owens,

Ahmed,

Lang Harman

et al. 2024

ChemBioChem

View full text Add to dashboard Cite

This review focuses on discussing natural products (NPs) that contain higher homologs of amino acids (homoAAs) in the structure as well as the proposed and characterized biosynthesis of these non‐proteinogenic amino acids. Homologation of amino acids includes the insertion of a methylene group into its side chain. It is not a very common modification found in NP biosynthesis as approximately 450 homoAA‐containing NPs have been isolated from four bacterial phyla (Cyanobacteria, Actinomycetota, Myxococcota, and Pseudomonadota), two fungal phyla (Ascomycota and Basidiomycota), and one animal phylum (Porifera), except for a few examples. Amino acids that are found to be homologated and incorporated in the NP structures include the following ten amino acids: alanine, arginine, cysteine, isoleucine, glutamic acid, leucine, phenylalanine, proline, serine, and tyrosine, where isoleucine, leucine, phenylalanine, and tyrosine share the comparable enzymatic pathway. Other amino acids have their individual homologation pathway (arginine, proline, and glutamic acid for bacteria), likely utilize the primary metabolic pathway (alanine and glutamic acid for fungi), or have not been reported (cysteine and serine). Despite its possible high potential in the drug discovery field, the biosynthesis of homologated amino acids has a large room to explore for future combinatorial biosynthesis and metabolic engineering purpose.

show abstract

First Report for the Electrooxidation of Antifungal Anidulafungin: Application to its Voltammetric Determination in Parenteral Lyophilized Formulation Using a Boron‐doped Diamond Electrode in the Presence of Anionic Surfactant

Özok¹,

Allahverdiyeva

Yardım

et al. 2022

Electroanalysis

View full text Add to dashboard Cite

In this paper, for the first time, the study of electrochemical oxidation and electroanalytical determination of anidulafungin (ANF), a semi‐synthetic echinocandin with antifungal activity was conducted. For this purpose, a commercially available boron‐doped diamond (BDD) electrode pretreated electrochemically (anodic and subsequent cathodic) was used. Employing cyclic voltammetry, the compound presented a single and irreversible oxidation step. The electrode process is controlled by a dual mechanism of diffusion and adsorption. A systematic study of various experimental conditions, such as the effect of electrode pretreatment, pH and the nature of the supporting electrolyte, surfactant, accumulation variables, and instrumental parameters on the adsorption behavior of ANF, was carried out by using square‐wave voltammetry. When the stripping mode (after 90 s accumulation at +0.3 V) was applied in 0.1 mol L−1 HNO3 containing 3×10−4 mol L−1 SDS, there was a linear dependence between the oxidation peak current at +1.29 V and the ANF concentration in the range from 0.1 to 10.0 μg mL−1 (8.8×10−8–8.8×10−6 mol L−1). The limit of detection value was found to be 0.021 μg mL−1 (1.8×10−8 mol L−1). Practical applicability of the proposed method was demonstrated in commercial parenteral dosage form.

show abstract

Review on Current Status of Echinocandins Use

Cited by 47 publications

References 116 publications

Echinocandins as Biotechnological Tools for Treating Candida auris Infections

Echinocandins as Biotechnological Tools for Treating Candida auris Infections

Natural Products That Contain Higher Homologated Amino Acids

First Report for the Electrooxidation of Antifungal Anidulafungin: Application to its Voltammetric Determination in Parenteral Lyophilized Formulation Using a Boron‐doped Diamond Electrode in the Presence of Anionic Surfactant

Contact Info

Product

Resources

About